Levofloxacin

Levofloxacin hydrochloride. Chemical name: (S)-(-)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-[1,4]-benzoxazine-6-carboxylic acid hydrochloride monohydrate.

1. Applicable to: urogenital system infections caused by sensitive bacteria, including simple and complicated urinary tract infections, bacterial prostatitis, urethritis or cervicitis of Neisseria gonorrhoeae (including those caused by enzyme-producing strains); 2. Applicable to: respiratory tract infections caused by sensitive bacteria, including acute attacks of bronchial infections and lung infections caused by sensitive Gram-negative bacilli; 3. Applicable to: gastrointestinal infections caused by sensitive bacteria, such as Shigella, Salmonella, enterotoxigenic Escherichia coli, Aeromonas hydrophilica, Vibrio parahaemolyticus, etc.; 4. Applicable to: typhoid fever caused by sensitive bacteria; 5. Applicable to: bone and joint infections caused by sensitive bacteria; 6. Applicable to: skin and soft tissue infections caused by sensitive bacteria; 7. Applicable to: systemic infections such as sepsis caused by sensitive bacteria.

Intravenous drip: 4 vials per day for adults, divided into 2 intravenous drips. For patients with severe infection and those whose pathogens are less sensitive to this product (such as Pseudomonas aeruginosa), the maximum daily dose can be increased to 6 vials, divided into 2 intravenous drips. (Each time, dilute with 5% glucose injection or 0.9% sodium chloride injection and drip intravenously.) The dose can be appropriately increased or decreased according to the type and symptoms of infection.

During medication, digestive symptoms such as nausea, vomiting, abdominal discomfort, diarrhea, loss of appetite, abdominal pain, and bloating may occur; neurological symptoms such as insomnia, dizziness, and headache; rash, itching, erythema, and redness, itching, or phlebitis at the injection site may occur. Transient liver function abnormalities may also occur, such as increased blood transaminase and increased serum total bilirubin. The incidence of the above adverse reactions is between 0.1 and 5%. Occasionally, blood urea nitrogen rises, fatigue, fever, palpitations, abnormal taste, and vascular pain after injection are observed, which are generally tolerated and disappear quickly after the end of the course of treatment.

Patients who are allergic to this product and fluoroquinolones are contraindicated.

Store in a cool place.

Zhejiang East-Asia Pharmaceutical Co., Ltd.

• Founded in:

  1998-02-06

• Address:

  Coastal Industrial City, Pubagang Town, Sanmen County, Zhejiang Province

• Tax NO.:

  913310001481183122

• Registered Funds:

  113.6 million yuan

• Website:

  Log in to view

• Email:

  Log in to view